Zhimin Geng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhimin Geng has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
Chen Chen
36 shared publicationsQi Li
26 shared publicationsDong Zhang
22 shared publications- Cheng Zhao
Xinhua Hospital 1 Department of General Surgery Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 shared publications - Danyang Shen
The First Affiliated Hospital of Soochow University 6 Department of General Surgery Suzhou, China
16 shared publications - Jiayun Zhu
Department of General Surgery Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Biliary Tract Disease Research Shanghai China
16 shared publications
Latest Publications
- Open Access
Deep Learning-Based Computer-Aided Detection and Diagnosis System for Malignant Biliary Stricture (With Video)
Background/Objectives: Malignant biliary stricture (MBS) remains difficult to diagnose accurately despite digital single-operator cholangioscopy (DSOC). We developed a deep learning (DL)-based computer-aided detection (CADe) and diagnosis (CADx) system for DSOC-based MBS assessment. Methods: This retrospective multicenter study included 149 patients from one center for model development and internal validation and 25 patients from two independent centers for external evaluation. CADe used a You Only Look Once version 11 (YOLOv11) architecture to localize irregular mucosa, abnormal vasculature, and nodular protrusions defined by the Carlos Robles-Medranda and Mendoza criteria. CADx used a Residual Network-18 classifier with gradient-weighted class activation mapping for interpretability. Results: CADe achieved a mean average precision at 50% intersection-over-union of 91.2%, with a precision of 92.0% and recall of 87.0%. CADx achieved a frame-level area under the receiver operating characteristic curve (AUC) of 0.960 in internal validation and 0.843 in external validation. External frame-level sensitivity was 52.0% and specificity was 95.2%. For the patient-level external endpoint, sensitivity was 85.7%, specificity was 94.4%, accuracy was 92.0%, and AUC was 0.881. Conclusions: The two-stage system combines localization of predefined cholangioscopic features with interpretable diagnostic classification. The small external cohort and marked reduction in frame-level sensitivity preclude firm conclusions regarding generalizability; prospective multicenter and live-procedure evaluation is required.
Open AccessDeep Learning-Based Computer-Aided Detection and Diagnosis System for Malignant Biliary Stricture (With Video)
Background/Objectives: Malignant biliary stricture (MBS) remains difficult to diagnose accurately despite digital single-operator cholangioscopy (DSOC). We developed a deep learning (DL)-based computer-aided detection (CADe) and diagnosis (CADx) system for DSOC-based MBS assessment. Methods: This retrospective multicenter study included 149 patients from one center for model development and internal validation and 25 patients from two independent centers for external evaluation. CADe used a You Only Look Once version 11 (YOLOv11) architecture to localize irregular mucosa, abnormal vasculature, and nodular protrusions defined by the Carlos Robles-Medranda and Mendoza criteria. CADx used a Residual Network-18 classifier with gradient-weighted class activation mapping for interpretability. Results: CADe achieved a mean average precision at 50% intersection-over-union of 91.2%, with a precision of 92.0% and recall of 87.0%. CADx achieved a frame-level area under the receiver operating characteristic curve (AUC) of 0.960 in internal validation and 0.843 in external validation. External frame-level sensitivity was 52.0% and specificity was 95.2%. For the patient-level external endpoint, sensitivity was 85.7%, specificity was 94.4%, accuracy was 92.0%, and AUC was 0.881. Conclusions: The two-stage system combines localization of predefined cholangioscopic features with interpretable diagnostic classification. The small external cohort and marked reduction in frame-level sensitivity preclude firm conclusions regarding generalizability; prospective multicenter and live-procedure evaluation is required.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Reagents and antibodies used in the study.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Reagents and antibodies used in the study.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Baseline characteristics of the entire cohort.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Baseline characteristics of the entire cohort.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Proportional hazards assumptions checked by schoenfeld residuals.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Proportional hazards assumptions checked by schoenfeld residuals.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Purpose:Nonmetastatic tumor-draining lymph nodes (TDLNs−) are central to initiating and sustaining antitumor immunity. The impact of their surgical removal on immunotherapy efficacy in recurrent biliary tract cancer remains unclear. We investigated the effect of TDLNs− dissection extent on treatment outcomes in this population.Experimental Design:This real-world study retrospectively analyzed clinical and survival data from 101 patients with recurrent biliary tract cancer who received immunotherapy across five Chinese hospitals (2018–2023). Patients were stratified by extent of TDLNs− dissection (≤6 vs. >6). Multiplex immunofluorescence (mIF) analysis of lymph node immune microenvironments was performed in a representative subset of patients (n = 20) from Sun Yat-sen Memorial Hospital.Results:Patients with ≤6 TDLNs− dissected (n = 59) achieved significantly longer progression-free survival (PFS) than those with >6 dissected (n = 42; HR, 0.48; 95% confidence interval, 0.31–0.73; P = 0.001), although there was no statistical difference in overall survival. The mIF staining analysis revealed that TDLNs− contained higher densities of TCF-1+PD-1−CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells and lower proportions of FOXP3+CD4+ regulatory T cells and TCF-1−PD-1+CD69+CD8+ terminally exhausted T cells compared with metastatic TDLNs (TDLNs+). Among immunotherapy responders, TDLNs− exhibited greater TCF-1+PD-1−CD8+ T-cell and CD11c+ cell densities than those in nonresponders. Importantly, a higher proportion of TCF-1+PD-1−CD8+ T cells in TDLNs− correlated with improved PFS, whereas extensive dissection of TDLNs− diminished this benefit.Conclusions:Excessive removal of TDLNs− compromises the efficacy of immunotherapy in recurrent biliary tract cancer. A selective lymphadenectomy approach that prioritizes clearance of TDLNs+ while preserving TDLNs− may optimize outcomes for patients receiving postoperative immunotherapy.See related commentary by Vonderheide, p. 2326
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Purpose:Nonmetastatic tumor-draining lymph nodes (TDLNs−) are central to initiating and sustaining antitumor immunity. The impact of their surgical removal on immunotherapy efficacy in recurrent biliary tract cancer remains unclear. We investigated the effect of TDLNs− dissection extent on treatment outcomes in this population.Experimental Design:This real-world study retrospectively analyzed clinical and survival data from 101 patients with recurrent biliary tract cancer who received immunotherapy across five Chinese hospitals (2018–2023). Patients were stratified by extent of TDLNs− dissection (≤6 vs. >6). Multiplex immunofluorescence (mIF) analysis of lymph node immune microenvironments was performed in a representative subset of patients (n = 20) from Sun Yat-sen Memorial Hospital.Results:Patients with ≤6 TDLNs− dissected (n = 59) achieved significantly longer progression-free survival (PFS) than those with >6 dissected (n = 42; HR, 0.48; 95% confidence interval, 0.31–0.73; P = 0.001), although there was no statistical difference in overall survival. The mIF staining analysis revealed that TDLNs− contained higher densities of TCF-1+PD-1−CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells and lower proportions of FOXP3+CD4+ regulatory T cells and TCF-1−PD-1+CD69+CD8+ terminally exhausted T cells compared with metastatic TDLNs (TDLNs+). Among immunotherapy responders, TDLNs− exhibited greater TCF-1+PD-1−CD8+ T-cell and CD11c+ cell densities than those in nonresponders. Importantly, a higher proportion of TCF-1+PD-1−CD8+ T cells in TDLNs− correlated with improved PFS, whereas extensive dissection of TDLNs− diminished this benefit.Conclusions:Excessive removal of TDLNs− compromises the efficacy of immunotherapy in recurrent biliary tract cancer. A selective lymphadenectomy approach that prioritizes clearance of TDLNs+ while preserving TDLNs− may optimize outcomes for patients receiving postoperative immunotherapy.See related commentary by Vonderheide, p. 2326
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Forest plots of PFS by subgroup for the TDLNs− ≤6 group versus the TDLNs− >6 group.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Forest plots of PFS by subgroup for the TDLNs− ≤6 group versus the TDLNs− >6 group.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Distribution of dissected TDLN counts.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Distribution of dissected TDLN counts.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Validation of the prognostic threshold for TDLNs− and assessment of the model robustness.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Validation of the prognostic threshold for TDLNs− and assessment of the model robustness.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Immunotherapy efficacy in patients with recurrent BTC.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Immunotherapy efficacy in patients with recurrent BTC.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Bootstrap distribution of the optimal cutoff value for dissected TDLNs−.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Bootstrap distribution of the optimal cutoff value for dissected TDLNs−.